This is true, but it is far too technical for a general audience. Even if you consider there is no difference seen in survival between doxorubicin and bisantrene, the side effect profile massively favours bisantrene - 25% of the doxorubicin arm patients ended up in heart failure!
I would add that they upped the dose of bisantrene after the first 45 patients from 260mg/m2 to 320mg/m2. Even after doing this the myleosupression rate was lower in the bisantrene arm suggesting the bisantrene patients were still being under dosed.
Ann: Race Appoints George Clinical for Phase 1 Trial of RC220, page-103
-
- There are more pages in this discussion • 44 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.58 |
Change
0.055(3.62%) |
Mkt cap ! $268.4M | |||
| Open | High | Low | Value | Volume |
| $1.56 | $1.61 | $1.56 | $106.0K | 67.13K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 649 | $1.58 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.59 | 3000 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |